GenomeWeb Top 40 Falls 7 Percent in May As Broader Market Delivers Mixed Results
The Dow Jones Industrial Average was down 3 percent, while the Nasdaq was up 6 percent, and the Nasdaq Biotech Index was down nearly 3 percent.
Two advisory firms have recommended ousting board chair John Thompson, while Illumina has magnified allegations that Carl Icahn's company is "Ponzi-like."
GenomeWeb Top 40 Falls 3 Percent in April Despite Gains in Broader Market
In comparison, the Dow Jones Industrial Average was up a fraction above 2 percent, while the Nasdaq was essentially flat, and the Nasdaq Biotech Index was up nearly 2 percent.
GenomeWeb Top 40 Rises 3 Percent in March, Following Broader Market
The Dow Jones Industrial Average was up 2 percent, while the Nasdaq was up 7 percent, and the Nasdaq Biotech Index was up 1 percent.
T2 Biosystems Warned by Nasdaq Over Listing Requirement
Nasdaq informed T2 Bio that its shares have failed to meet a minimum $1 per share closing price for 30 consecutive days, which may result in the delisting of the firm's shares.